Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
In the phase 2 trial, 86% of EVX-01 neoantigen targets triggered a tumor-specific immune response in patients.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Evaxion (EVAX) will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting in November.
The data come from a phase 2 trial of EVX-01 plus pembrolizumab in advanced melanoma. They examine effects across the immune system beyond vaccine-specific T-cell responses. Oral and poster presentations are scheduled for November 6 and 7 in Phoenix.
Complete three-year clinical data will be presented at ESMO on October 24, 2026. At two years, 12 of 16 patients had objective clinical responses, a 75% objective response rate, including four complete responses. The update reported 92% of patients still responding at two-year follow-up and no relapses. Patients received EVX-01 alone in the third year; Evaxion expects the data to offer insight into the vaccine's effects without anti-PD-1 therapy.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointTwo-year 75% objective response rate: 12 of 16 patients responded, including four complete responses.
- Minor pointTwo-year follow-up showed 92% of patients still responding, with no relapses observed.
- Minor point86% of EVX-01 neoantigen targets triggered a tumor-specific immune response in phase 2 patients.
Negative
- None.
Key Figures
- Objective response rate
- 75% (12 of 16 patients)
- Previously reported two-year phase 2 results
- Complete responses
- 4 patients
- Previously reported two-year phase 2 results
- Patients still responding
- 92%
- At two-year follow-up; no relapses were observed
- Neoantigen targets triggering immune response
- 86%
- Previously reported EVX-01 trial results
Key Terms
objective response rate medical
anti-PD-1 medical
neoantigen medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- New immune data from the phase 2 trial with EVX-01 to be presented both in an oral and poster presentation
- New data follows from the three-year clinical update for EVX-01 to be provided at the European Society for Medical Oncology (ESMO) 2026 congress on October 24, 2026
COPENHAGEN, Denmark, October 2, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will present new immune data for AI-designed personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place in Phoenix, Arizona, November 4-8, 2026.
The new data will reflect the systemic immunomodulatory effects of EVX-01 plus pembrolizumab beyond vaccine-specific T-cell responses using comprehensive immune profiling. It will be presented both in an oral and poster presentation at the SITC meeting.
The new immune data stems from the phase 2 trial investigating EVX-01 in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with advanced melanoma. Each patient enrolled in the trial received a unique vaccine designed and manufactured based on their individual biology. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
The complete three-year clinical data from the phase 2 trial will be presented at the European Society for Medical Oncology (ESMO) 2026 congress on October 24, 2026. Two-year data demonstrated an Objective Response Rate (ORR) of
In the third year, patients received EVX-01 as stand-alone therapy, meaning the data will offer insight into the vaccine’s effect also when not administered in combination with anti-PD-1 therapy. Further, the data may also provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune response.
SITC oral and poster presentation details:
- Abstract title: EVX-01 personalized AI-designed vaccine plus pembrolizumab induce neoantigen-specific T-cell responses and systemic immune modulation in advanced melanoma
- Abstract#: 502
Oral presentation:
- Session: 105b: Rapid Oral - Clinical 1
- Location: Phoenix Convention Center, West Building-300 Level - 301BC
- Date/Time: Friday, November 6, 2026, 12:30-1:30pm MT / 20:30-21:30 CET
- Presenter: Mads Lausen, Senior Scientist at Evaxion
Poster presentation:
- Session: Poster Session
- Location: Phoenix Convention Center, North Building-Lower Level - Exhibition Halls 4-6
- Date/Time: Saturday, November 7, 2026, 12:30-1:30pm & 6:40-8:10pm MT / 20:30-21:30 CET & 02:40-04:10 CET (Sunday, November 8)
- Presenter: Mads Lausen, Senior Scientist at Evaxion
About EVX-01
EVX-01 is a personalized peptide-based cancer vaccine intended for first-line treatment of multiple advanced solid cancer tumors. It is currently being evaluated as a treatment of advanced melanoma and is Evaxion’s lead clinical asset.
Designed with our AI-Immunology™ platform, EVX-01 is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient's immune system to fight off cancer by mounting a targeted response against tumor-specific neoantigens.
In the phase 2 trial in patients with advanced melanoma (skin cancer), EVX-01 has demonstrated an Objective Response Rate (ORR) of
Contact information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai
About Evaxion
Evaxion is a pioneering clinical-stage TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer as well as infectious and autoimmune diseases.
With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development.
We have developed a pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.
For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Evaxion present EVX-01 three-year clinical data and new immune data?
Evaxion will present complete three-year clinical data at ESMO on October 24, 2026, followed by new immune data at SITC in Phoenix. The SITC oral presentation is scheduled for November 6 and the poster presentation for November 7.
What did Evaxion's EVX-01 phase 2 trial show at two years?
The trial showed a 75% objective response rate, with 12 of 16 patients having objective clinical responses, including four complete responses. At two-year follow-up, 92% of patients were still responding and no relapses were observed. The trial investigated EVX-01 in combination with pembrolizumab in advanced melanoma.